`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICEUNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARDBEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS, LLC
`
`ARGENTUM PHARMACEUTICALS, LLCARGENTUM PHARMACEUTICALS, LLC
`
`PETITIONER
`
`
`
`PETITIONERPETITIONER
`
`V.
`
`
`
`V.V.
`
`ALCON RESEARCH, LTD
`
`ALCON RESEARCH, LTDALCON RESEARCH, LTD
`
`PATENT OWNER
`
`
`
`PATENT OWNERPATENT OWNER
`
`U.S. PATENT NO. 8,791,154
`
`U.S. PATENT NO. 8,791,154U.S. PATENT NO. 8,791,154
`
`INTER PARTES REVIEW CASE NO. IPR2016-00544
`
`
`
`INTER PARTES REVIEW CASE NO. IPR2016-00544INTER PARTES REVIEW CASE NO. IPR2016-00544
`
`DECLARATION OF ERNING XIA, PH.D
`
`DECLARATION OF ERNING XIA, PH.DDECLARATION OF ERNING XIA, PH.D
`
`
`
`000001000001
`
`
`
`ARGENTUM PHARM. 1002ARGENTUM PHARM. 1002
`
`ARGENTUM PHARM. 1002
`
`000001
`
`
`
`TABLE OF CONTENTS
`
`TABLE OF CONTENTS
`
`Introduction .................................................................................................... ..3
`
`III.
`
`IV.
`
`Claim Construction ...................................................................................... ..11
`
`VI.
`
`State Of The Art ........................................................................................... ..12
`
`POLYETHYLENE GLYCOL ..................................................................... ..14
`
`Introduction ...................................................................................................... 3(cid:3)
`I. (cid:3)
`II. (cid:3) Background and Qualifications ....................................................................... 4(cid:3)
`Background and Qualifications ..................................................................... ..4
`III. (cid:3) Person Of Ordinary Skill In The Art ............................................................... 7(cid:3)
`Person Of Ordinary Skill In The Art ............................................................. ..7
`IV. (cid:3) The Technology Claimed In The ’154 Patent ................................................. 9(cid:3)
`The Technology Claimed In The ’154 Patent ............................................... ..9
`V. (cid:3) Claim Construction ........................................................................................ 11(cid:3)
`VI. (cid:3) State Of The Art ............................................................................................. 12(cid:3)
`POLYETHYLENE GLYCOL ....................................................................... 14(cid:3)
`POLYVINYLPYRROLIDONE .................................................................... 17(cid:3)
`HYDROXYPROPYLMETHYLCELLUOSE ............................................... 19(cid:3)
`CYCLODEXTRINS AND COMPLEXES OF CYCLODEXTRIN
`WITH DRUGS AND SOLUBILIZING POLYMERS ....................... 20(cid:3)
`BAC 27(cid:3)
`BORATES ..................................................................................................... 30(cid:3)
`POLYOL ........................................................................................................ 31(cid:3)
`OSOMOLALITY AND pH ........................................................................... 32(cid:3)
`OSOMOLALITY AND pH ......................................................................... ..32
`VII. (cid:3) Summary Of My Conclusions ....................................................................... 33(cid:3)
`Summary Of My Conclusions ..................................................................... ..33
`A. (cid:3) Ground 1: Obviousness based on Bhowmick in view of Yanni
`and Castillo .......................................................................................... 33(cid:3)
`B. (cid:3) Ground 2: Obviousness based on Schneider in view of
`Hayakawa, Bhowmick and Castillo .................................................... 40(cid:3)
`Hayakawa, Bhowmick and Castillo .................................................. ..4O
`
`POLYVINYLPYRROLIDONE .................................................................. ..17
`
`HYDROXYPROPYLMETHYLCELLUOSE ............................................. .. 19
`
`CYCLODEXTRINS AND COMPLEXES OF CYCLODEXTRIN
`
`WITH DRUGS AND SOLUBILIZING POLY1\/[ERS ..................... ..20
`
`BAC 27
`
`BORATES ................................................................................................... ..3O
`
`POLYOL ...................................................................................................... ..3 1
`
`VII.
`
`A.
`
`Ground 1: Obviousness based on Bhowmick in View of Yanni
`
`and Castillo ........................................................................................ ..33
`
`B.
`
`Ground 2: Obviousness based on Schneider in View of
`
`2
`2
`000002
`
`000002
`
`
`
`I, Erning Xia, Ph.D., hereby declare as follows.
`
`I.
`
`Introduction
`
`1.
`
`I have been retained as an expert witness on behalf of ARGENTUM
`
`PHARMACEUTICALS, LLC., ("ARGENTUM") for the above-captioned inter
`
`partes review (IPR). I am being compensated for my time by the hour in preparing
`
`this declaration, but my compensation is not tied to the outcome of this matter.
`
`2.
`
`I understand that this Declaration accompanies a petition for IPR
`
`involving U.S. Patent No. 8,791,154 ("the '154 patent"), Ex. 1001, which resulted
`
`from U.S. Patent Application No. 13/475,607 ("the '607 application"), filed May
`
`18, 2012. I also understand that the '154 patent claims priority to U.S. Provisional
`
`Patent Application No. 61/548,957, filed Oct 19, 2011 and U.S. Provisional Patent
`
`Application No. 61/487,789, filed May 19, 2011.
`
`3.
`
`The '154 patent names Daniel A. Gamache, Laman Alani, Malay
`
`Ghosh, Francisco Javier Galán, Núria Carreras Perdiguer, and Onkar N. Singh as
`
`the inventors. The '154 patent issued on June 29, 2014 from the '607 application. I
`
`understand that, according to the United States Patent and Trademark Office
`
`("USPTO") records, the '154 patent is currently assigned to Alcon Research, Ltd.
`
`("Alcon".)
`
`3
`
`000003
`
`
`
`4.
`
`In preparing this Declaration, I have reviewed the '154 patent, the
`
`granted claims (1-27), the file history of the ‘154 patent, and each of the
`
`documents cited herein, in light of general knowledge in the art. In formulating
`
`my opinions, I have relied upon my experience, education, and knowledge in the
`
`relevant art. In formulating my opinions, I have also considered the viewpoint of a
`
`person of ordinary skill in the art ("POSA") (i.e., a person of ordinary skill in the
`
`art of ophthalmic drug formulations and treatment). Throughout this declaration,
`
`in rendering my opinion, I have considered what the viewpoint of a POSA would
`
`have been prior to May 19, 2011, the filing date of U.S. Provisional Patent
`
`Application No. 61/487,789, to which the challenged '154 patent claims priority.
`
`In the event that the priority claim to the ‘789 patent is deemed invalid, I have also
`
`considered what the viewpoint of a POSA would have been prior to October 11,
`
`2011, the filing date of U.S. Provisional Patent Application No. 61/548,957, to
`
`which the challenged ‘154 patent also claims priority.
`
`II. Background and Qualifications
`
`5.
`
`I am an expert in the field of ophthalmic drug formulation, and I
`
`have been an expert in this field since prior to 2003. I am presently employed by
`
`Fulcrum International Technologies, Inc. I obtained a Bachelor of Science degree
`
`in Pharmacy from Nanjing College of Pharmacy in 1982, a Master of Science
`
`4
`
`000004
`
`
`
`degree in Biopharmaceuticals from China Pharmaceutical University in 1985, and
`
`a Ph.D. in Pharmaceutics from the University of Iowa in 1995.
`
`6.
`
`I was an Assistant Professor and Research Associate for the College
`
`of Pharmacy at the China Pharmaceutical University from August 1985 to
`
`December 1987, a Research Associate at Illinois State University from January
`
`1988 to December 1989, and a Research and Teaching Assistant for the University
`
`of Iowa, College of Pharmacy from 1990 to 1995. After receiving my Ph.D. in
`
`Pharmaceutics, I held the positions of Senior Formulation Process Scientist and
`
`Principal Formulation Process Scientist with Bausch & Lomb in Rochester, NY
`
`from 1995-1999 and 1999-2001, respectively. I subsequently held the positions of
`
`Senior Principal Formulation Process Scientist from 2001-2004, Research Fellow
`
`from 2004-2005, and Site Leader/Research Fellow from 2006-2008 at Bausch &
`
`Lomb.
`
`7.
`
`I have served as Program Director and Research Fellow at Valeant
`
`Pharmaceuticals in Rochester, NY from 2009-2013. I currently hold the position of
`
`Distinguished Research Fellow and Chief Technology Officer ("CTO") at Fulcrum
`
`International Technologies, Inc. ("Fulcrum") and have served in this position since
`
`September of 2013.
`
`5
`
`000005
`
`
`
`8.
`
`I have experience formulating topical ophthalmic products for
`
`treating dry eye, including products that decrease the evaporation of natural tears
`
`and products that increase tear production. While serving as CTO at Fulcrum, I
`
`helped develop a water-soluble based nutritional product for eye fatigue called 7-
`
`Hours™. Previously, I led Vision Care research initiatives as Program Director at
`
`Valeant Pharmaceuticals and dry eye initiatives and dry eye portfolio management
`
`as a Research Fellow at Bausch & Lomb in Rochester, NY. Also, while at Bausch
`
`& Lomb, my colleagues and I often consulted with physicians to determine the
`
`current ophthalmic needs in the market, and then made efforts to meet those needs.
`
`9.
`
`I have received several honors in my career, including the Bausch &
`
`Lomb In Focus Recognition in 2010, the Bausch & Lomb CSO Innovation Award
`
`in 2007, the National Award for Science Spectrum Trailblazer in 2005, and the
`
`National Emerald Award for Career Achievement in Industry in 2004.
`
`10.
`
`During my nearly 30 years of experience in topical ophthalmic drug
`
`formulation, I have authored or co-authored 36 scientific articles. I am also a
`
`named inventor on 106 U.S. patents and patent applications. Each publication,
`
`patent, and patent application is listed in my curriculum vitae, Ex. 1024.
`
`11.
`
`Accordingly, I am an expert in the field of topical ophthalmic drug
`
`formulation. My full background is detailed in my curriculum vitae, Ex. 1024.
`
`6
`
`000006
`
`
`
`III. Person Of Ordinary Skill In The Art
`
`12.
`
`I understand that a person of ordinary skill in the art ("POSA") is a
`
`hypothetical person who is presumed to be aware of all of the pertinent art, thinks
`
`along conventional wisdom in the art, and is a person of ordinary creativity. A
`
`POSA with respect to topical eye formulations would have had knowledge of the
`
`scientific literature regarding inflammatory eye disorders and useful therapies
`
`including, e.g., topical aqueous solutions and their formulation into delivery
`
`vehicles, as of May 2011.
`
`13. With respect to the subject matter of the '154 patent, a POSA typically
`
`would have had: (i) an M.D., Pharm. D. or Ph.D. in chemistry, biochemistry,
`
`pharmaceutics, or in a related field in the biological or chemical sciences, and have
`
`at least about two years of experience in the treatment ocular diseases and
`
`formulations used to treat ocular diseases, including topical pharmaceuticals for
`
`use in the eye; or (ii) a Master's degree in chemistry, biochemistry, pharmaceutics,
`
`or in a related field in the biological or chemical sciences, and have at least about
`
`five years of experience in the treatment of ocular diseases and formulations used
`
`to treat ocular diseases, including topical pharmaceuticals for use in the eye; or (iii)
`
`a bachelor’s degree in pharmacy, chemistry, biochemistry, pharmaceutics, or in a
`
`related field in the biological or chemical sciences, and have at least about 10 years
`
`7
`
`000007
`
`
`
`of experience in the treatment of ocular diseases and formulations used to treat
`
`ocular diseases, including topical pharmaceuticals for use in the eye. The POSA
`
`would have an understanding of the basis of ocular allergy including knowledge of
`
`the structure and constitution of conjunctiva of the eye, Immunoglobulin E (IgE)
`
`antigen stimulated histamine release, cell-based and animal models and assays for
`
`assessing effectiveness of ophthalmic treatments, and knowledge of ophthalmic
`
`formulation excipients. These descriptions are approximate, and a higher level of
`
`education or specific skill might make up for less experience, and vice-versa.
`
`14. A POSA typically would work as part of a multidisciplinary team and
`
`draw upon not only his or her own skills, but also take advantage of certain
`
`specialized skills of others in the team to solve a given problem. For example, a
`
`formulations chemist with knowledge of a wide array of excipients suitable for use
`
`in ophthalmic formulations and their properties may be part of the team. A
`
`clinician having experience in treating allergic disorders of the eye with topical
`
`pharmaceuticals may also be part of the team.
`
`15.
`
`I believe that I would qualify as a person of at least ordinary skill in
`
`the art as of May 19, 2010.
`
`8
`
`000008
`
`
`
`IV. The Technology Claimed In The ’154 Patent
`
`16. The ’154 patent relates to ophthalmic aqueous solutions for the
`
`treatment of ocular allergic conjunctivitis containing the drug olopatadine, and
`
`methods of treating ocular allergy symptoms in human. Ex. 1001, Abstract, 2:41-
`
`45, 3:1-2, claims 1, 4, 8, 12 and 21. These compositions contain “relatively high”
`
`concentrations of olopatadine including at least 0.67 w/v %, 0.7 w/v %, and not
`
`more than 1.0 w/v% olopatadine. Id., 2:42-44; 4:1-2; claims 1, 4, 8 and 21. In
`
`order to solubilize the relatively high concentrations of olopatadine in a stable
`
`manner, the inventors purport to provide a unique set of excipients for solubilizing
`
`the olopatadine. Id., 3:28-29. The excipients include a cyclodextrin derivative
`
`selected from SAE-(cid:533)-cyclodextrin, HP-(cid:534)-cyclodextrin, HP-(cid:533)-cyclodextrin or
`
`combinations thereof. Id., 2:45-52; claims 1, 4, 8 and 21. Typically, the solution
`
`contains at least 0.5 w/v % but no greater than 2.0 w/v % HP- (cid:534) -cyclodextrin. Id.,
`
`4:65-67; and claims 8 and 21. The composition also includes the common lactam
`
`polymer polyvinylpyrrolidone (PVP) to aid in the solubilization of the olopatadine,
`
`and a polyether (e.g., polyethylene glycol (PEG)) for enhancing solubility and/or
`
`aiding in achieving the desired tonicity. Id., 2:52-57; claims 1, 4, 8 and 21. The
`
`solutions typically contain 2.0 w/v % to 6.0 w/v % PVP and 2.0 w/v % to 6.0 w/v
`
`% PEG having a molecular weight of 300 to 500. Id. claims 4, 8 and 21.
`
`9
`
`000009
`
`
`
`17. The compositions also include a preservative such as benzalkonium
`
`chloride (BAC), as well as borate and/or polyol to aid in achieving desired
`
`preservation. Id., 2:60-67; claims 1, 2, 3, 4, 8 and 21. Typically, the compositions
`
`contain greater than 0.003 w/v % but less than 0.03 w/v % BAC. Id., 9:6-14; claim
`
`21. In order to enhance the residence time of the composition upon the cornea
`
`when the composition is topically administered, the compositions may contain
`
`viscosity enhancing agents such as hydroxylpropylmethyl cellulose (HPMC) at a
`
`concentration of at least 0.15 w/v % but no greater than 1.0 w/v %. Id., 6: 41-50;
`
`7: 9-14; claims 15, 16, 17, and 22. The compositions also include water.(cid:3)Id., 4: 24-
`
`26; Examples 1-2; claims 1, 4, 8, and 21. The pH of the aqueous solution is 6.0 to
`
`7.8 and the osmolality of the solution is 200 to 400 mOsm/kg. Id., 10: 4-9; claim
`
`21.
`
`18. The aqueous solutions may be administered to a human to treat at
`
`least one ocular allergy symptom such as ocular itching. Id., 3:1-5; claims 12 and
`
`14. The solution is topically applied to an eye by dispensing at least one drop of
`
`the solution to the eye. Id., claim 13.
`
`19. The ophthalmic compositions of the ’154 patent are also purported to
`
`provide multiple advantages over previous olopatadine compositions. Among the
`
`advantages alleged for the claimed compositions are the following. First,
`
`10
`
`000010
`
`
`
`compositions containing HP-(cid:534)-CD were unexpectedly found to be “more
`
`susceptible to preservation” than those with while simultaneously having solubility
`
`characteristics similar to the (cid:533)-cyclodextrin derivatives also discussed. Id., 11: 33-
`
`38. Second, although cyclodextrins are known to “entrap other drugs in a manner
`
`that does not allow the drugs to later release and show efficacy, HP-(cid:534)-CD does not
`
`interfere with olopatadine efficacy. Id., 45-50. However, as discussed below, the
`
`claimed ophthalmic compositions of the ’154 patent would have been obvious to a
`
`POSA and do not provide any surprising results or advantages.
`
`V. Claim Construction
`
`20.
`
`I understand that terms of the claims are to be given their broadest
`
`reasonable interpretation as understood by a POSA in light of the language of the
`
`claims and specification of the '154 patent.
`
`21.
`
`“w/v %” Claims 1, 4, 8, 16,17, 21, and 22 each recite components in
`
`terms of “w/v %.” While the ’154 Patent states the term means weight volume
`
`percent (’154 Patent, 3:41-43), it does not provide the units used in determining the
`
`weight volume percent. The expression “w/v %” is proposed to describe the mass
`
`of the component in grams per 100 milliliters of solution multiplied by 100, as this
`
`definition is the standard used in the formulations and topical eye pharmaceutical
`
`industries. Pharmaceutical Calculations, 13th Ed., Ansell, 2010, Ex. 1036, 82-83.
`
`11
`
`000011
`
`
`
`VI. State Of The Art
`
`22. Olopatadine hydrochloride ([(Z)-3-(dimethylamino)propylidene]-
`
`6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride) is a selective
`
`histamine H1-receptor antagonist that is used for the treatment of ocular symptoms
`
`of seasonal allergic conjunctivitis and has the following formula:
`
` PATADAY® label; Ex. 1038, 6.
`
`.
`
`23. Olopatadine and its pharmaceutically acceptable salts are disclosed in
`
`EP 0214779, U.S. Pat. No. 4,871,865, EP 0235796 and U.S. Pat. No. 5,116,863
`
`(Exs. 1029, 1027, 1032, 1028). U.S. Pat. No. 5,116,863 discloses olopatadine (Z-
`
`11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz [b,e]oxepin-2-acetic acid)
`
`as a compound having an anti-allergic activity and is known to be an effective
`
`treatment for symptoms of allergic rhinitis and urticaria (e.g., sneezing, nasal
`
`discharge and nasal congestion), as well as in the treatment of various skin
`
`12
`
`000012
`
`
`
`diseases, such as eczema and dermatitis. Ex. 1028, 2:1-14. The compound may be
`
`administered in a solid oral dosage form or as an ophthalmic solution. Id., 1:18-19.
`
`24.
`
`In the U. S, olopatadine hydrochloride is commercially available
`
`under the brand names PATANOL® and PATADAY® as 0.1 % and 0.2% sterile
`
`ophthalmic solutions, respectively, both marketed by Alcon. Exs, 1037, 1038
`
`PATANOL® is indicated for the treatment of signs and symptoms of allergic
`
`conjunctivitis and PATADAY® for the treatment of ocular itching associate with
`
`eye allergy. Id. According to its labelling information, each mL of PATANOL®
`
`contains olopatadine hydrochloride equivalent to 0.1% olopatadine, 0.01%
`
`benzalkonium chloride, and unspecified amounts of sodium chloride, dibasic
`
`sodium phosphate, hydrochloric acid and/or sodium hydroxide (to adjust pH) and
`
`purified water. Ex. 1037. According to its labelling information, each mL of
`
`PATADAY® solution contains olopatadine hydrochloride equivalent to 0.2%
`
`olopatadine, and inactives such as 0.01% benzalkonium chloride and unspecified
`
`amounts of povidone, dibasic sodium phosphate, sodium chloride, edentate
`
`disodium, hydrochloric acid/sodium hydroxide (to adjust pH) and purified water.
`
`Ex. 1038.
`
`13
`
`000013
`
`
`
`POLYETHYLENE GLYCOL
`
`25. Polyethylene glycol, referred to as “PEG,” is a polymer containing
`
`repeating -CH2CH2O- subunits and is used in the pharmaceutical industry as a
`
`solvent, plasticizer, surfactant, ointment base, and a tablet and capsule lubricant,
`
`among others. PEG has low toxicity, with absorption into the body less than 0.5%.
`
`“PEG 400" indicates that the average molecular weight of the specific PEG is 400.
`
`Ex. 1061, 4:2-4.
`
`26. Polyethylene glycol 400 is also recognized by the U.S. Food and Drug
`
`Administration as an active ingredient on its own – an ophthalmic demulcent. 21
`
`C.F.R. §349.12, revised as of April 1, 2001, Ex. 1057. The U.S. Food and Drug
`
`Administration authorizes an ophthalmic product containing 0.2 – 1.0% PEG 400
`
`to recite that the product provides the pharmaceutical benefits of protecting and
`
`lubricating mucous membrane surfaces and relieving dryness and irritation. Id.
`
`27. PEG 400 itself has long been used to enhance the aqueous solubility
`
`of hydrophobic, poorly water soluble compounds. As noted in AAPS Pharm. Sci.
`
`Tech, 4 (1), pp 1-5, 2003 (“Nandi”), “[p]olyethylene glycol (PEG)-400 is one of
`
`the most widely used cosolvents for improving the aqueous solubility of
`
`hydrophobic drugs.” Ex. 1015, 1. For example, valdecoxib has a water solubility
`
`of 0.01 milligrams per milliliter (mg/mL), which is equivalent to 0.1 w/v%. Ex.
`
`14
`
`000014
`
`
`
`1035, p. 1588 (Table 1). In studies of the solubility of valdecoxib in various
`
`PEG:water solutions, a mixture having a volumetric ratio of 1:99 PEG 400:water
`
`was examined. Id. The weight/volume percent of the PEG 400 may be calculated
`
`from the volumetric ratio. Because the density of PEG 400 is 1.128 g/mL, this
`
`mixture contains 1.126 g PEG 400 per 99 mL of water. Dividing the weight of the
`
`PEG 400 by the volume of water provides a value of about 1.1 w/v% PEG 400 in
`
`water. At 1.1 w/v% PEG 400, the solubility of valdecoxib increased to 0.92
`
`mg/mL (or 9.2 w/v% from 0.1 w/v%). Id.
`
`28. PEG 400 was also understood to enhance the physical stability of
`
`olopatadine-containing solutions at PEG 400 concentrations of 2 w/v%. U.S. Pat.
`
`No. 6,995,186 (“Castillo”) discusses topical solutions for treating allergic or
`
`inflammatory disorders of the eye where the solutions include approximately 0.2-
`
`0.6 w/v% olopatadine. Ex. 1006, 2:13-19, 32-34. In Table 5, Castillo discloses
`
`Formulation M, a solution that contains 0.222 w/v% olopatadine hydrochloride
`
`(equivalent to 0.2 w/v% olopatadine), 2 w/w% PEG 400, about 0.01 w/w%
`
`benzalkonium chloride, 0.5 w/w% dibasic sodium phosphate (i.e., Na2HPO4), 0.3
`
`w/w% sodium chloride, 0.01 w/w% edetate disodium, and where the solution has a
`
`15
`
`000015
`
`
`
`pH of 7.1 Additional solutions were disclosed with the same makeup except for the
`
`addition of 2 w/w% PVP with a weight average molecular weight of 58,000
`
`(Formulations N and L respectively), the omission of PEG 400 but including the
`
`same type of PVP (Formulations K and N) or 0.333% w/w olopatadine.HCl and
`
`the same three PEG 400/PVP variations (Formulations Q, R, S). Ex. 1006,
`
`Example 7, Table 5. These solutions were subjected to freeze-thaw stability
`
`studies. The studies were carried out under two sets of conditions: the first
`
`involved solutions with added pumice as a seeding agent to facilitate precipitation
`
`and crystallization, and the second lacked pumice. (Notably, while the example
`
`refers to the same seed as “Example 4”, this is clearly a typographical error
`
`because Example 4 does not include a seeding agent while Example 6 includes the
`
`pumice seeding agent.) Three vials of each solution, were tested under each set of
`
`conditions. Each formulation was subjected to up to six freeze-thaw cycles where
`
`one cycle was three days at low temperature (either 0 °C. or –20 °C.), followed by
`
`one day at uncontrolled room temperature. The solutions were then visually
`
`inspected and the results recorded. As illustrated in Table 6, none of the
`
`formulations containing PEG 400 (Formulations L, M & R) showed any
`
`precipitation. Id., Table 6. Although solutions with only PVP also avoided
`
`1 Table 5 lists the components in w/w% based on water. Because 1 mL of water is
`
`about 1 g, w/w% is essentially equivalent to w/v% in this instance.
`
`16
`
`000016
`
`
`
`precipitation at 0.222% w/w olopatadine (formulations K, N, O), Only
`
`Formulation R with PEG 400 avoided precipitation at 0.333% w/w olopatadine.
`
`Thus, Castillo shows that using PEG 400, both alone and with PVP, provides
`
`olopatadine solutions with enhanced stability. Id., Example 7, Tables 5 &6
`
`(Formulations L, M, & R).
`
`29. Thus, Castillo shows that, in addition to the well-known solubility
`
`enhancement and demulcent properties of PEG 400, 2 w/v% PEG 400 had been
`
`demonstrated to enhance the stability of olopatadine containing solutions. Further,
`
`Schneider describes aqueous solution compositions of olopatadine which include
`
`polymers such as PEG that may act as lubricants or viscosity agents. Ex. 1007,
`
`[0052].
`
`POLYVINYLPYRROLIDONE
`
`30. Polyvinylpyrrolidone also goes by the names “PVP” or “povidone.”
`
`PVP is a known demulcent, and the U.S. Food and Drug Administration authorizes
`
`an ophthalmic product containing 0.1 – 2.0% PVP to recite that the product
`
`provides the pharmaceutical benefits of protecting and lubricating mucous
`
`membrane surfaces and relieving dryness and irritation. There are various varieties
`
`of PVP based on the molecular weight, as illustrated in the table below.
`
`17
`
`000017
`
`
`
`Molecular
`
`10,000
`
`30,000
`
`40,000
`
`58,000
`
`360,000
`
`Weight
`
`K-value
`
`12-18
`
`27-33
`
`28-32
`
`29-32
`
`90-103
`
`Synonym
`
`PVP K15
`
`PVPK30
`
`PVP K30
`
`PVP K30
`
`PVP K90
`
`Ex. 1058.
`
`31. The “K-value” is the Fikentscher K-value, derived from a solution
`
`viscosity of the polymer in water, thus it is related to an intrinsic viscosity and the
`
`average molecular weight. “Viscosity correlation for aqueous PVP solutions”, J
`
`Applied Polymer Science, Volume 90, Issue 4 Page 1153-1155, 2003, Ex. 1059,
`
`Abstract, 1st Col. As the synonyms for PVP are related to its K-value, it is
`
`generally more accurate to discuss PVP in terms of its weight average molecular
`
`weight.
`
`32. Prior to May 19, 2010, PVP was known to increase the solubility and
`
`enhance the physical stability of olopatadine-containing solutions. PVP was
`
`known to be generally beneficial for inclusion in ophthalmic anti-allergy
`
`compositions. PVP was known to be generally beneficial for inclusion in
`
`ophthalmic anti-allergy compositions. Ex. 1043, 124. As discussed above, Castillo
`
`discloses topical solutions for treating allergic or inflammatory disorders of the eye
`
`where the solutions include approximately 0.2-0.6% olopatadine and are effective
`
`as once-a-day products. Ex. 1006, 2:13-19. In addition to the olopatadine, Castillo
`
`18
`
`000018
`
`
`
`discloses including an amount of PVP sufficient to enhance the stability of the
`
`solutions. Id., 2:19-22. The particular concentrations of PVP suggested by
`
`Castillo are 0.1 w/v% to 3 w/v%, where the weight average molecular weight of
`
`the PVP used is disclosed to be 5,000 to 1,600,000, but most preferably from
`
`50,000 to 60,000. Id., 3:17-25. Schneider teaches aqueous solution compositions
`
`of olopatadine which include polymers such as PVP that may act as lubricants or
`
`viscosity agents. Ex. 1007, [0052]. Likewise, Hayakawa describes using PVP as
`
`the viscous vehicle for its topical ophthalmic formulations containing olopatadine.
`
`Ex. 1008, 6:50-58.
`
`HYDROXYPROPYLMETHYLCELLUOSE
`
`33. Hydroxypropylmethylcelluose (also known as “hypromellose” or
`
`HPMC) is recognized by the U.S. Food and Drug Administration as an ophthalmic
`
`demulcent at concentrations of 0.2 to 2.5%. C.F.R. §349.12. On July 3, 2003, the
`
`U.S. Food and Drug Administration (based on an action and recommendation from
`
`the United States Pharmacopeia (USP)) changed the listed name of
`
`hydroxypropylmethyl-cellulose to “hypromellose” but did not change its
`
`classification as an ophthalmic demulcent. 68 Fed. Reg. 106, 32981-32983, Ex.
`
`1060. Thus, much like PEG 400 and polyvinylpyrrolidone, the U.S. Food and
`
`Drug Administration authorizes an ophthalmic product containing 0.2 – 2.5%
`
`hydroxypropylmethylcelluose to be labeled as providing the pharmaceutical
`
`19
`
`000019
`
`
`
`benefits of protecting and lubricating mucous membrane surfaces and relieving
`
`dryness and irritation. Ex. 1057.
`
`34. Bhowmick teaches the use of HPMC to further stabilize the inclusion
`
`complexes of olopatadine and cyclodextrins in aqueous topical solutions. Ex.
`
`1004, 2:26-27; 6:23-26. Bhowmick discloses that the HPMC may be used at
`
`concentrations ranging from about 0.001 % to about 5%, and more preferably in
`
`concentrations ranging from about 0.01 % to about 1 % w/v. Id., 7:10-13. Castillo
`
`provides a working example with HPMC (and absent PVP) that illustrates the same
`
`enhanced stability provided by PVP. Compare Ex. 1006, Example 6, Tables 3 & 4
`
`(Formulation H) with id., Example 7, Tables 5 & 6. Schneider describes aqueous
`
`solution compositions of olopatadine which include polymers that may act as
`
`lubricants or viscosity agents, such as HPMC, PEG, and PVP. Ex. 1007, [0052].
`
`Schneider explains that while there are solubility enhancing components for
`
`olopatadine, PDE4 itself increases the solubility of olopatadine in aqueous
`
`solutions. Id., [0042]
`
`CYCLODEXTRINS AND COMPLEXES OF CYCLODEXTRIN WITH
`DRUGS AND SOLUBILIZING POLYMERS
`35. Cyclodextrins are a group of structurally related natural products
`
`formed during bacterial digestion of cellulose and commonly used as
`
`pharmaceutical excipients for the solubilization of hydrophobic drugs. Ex. 1015,
`
`20
`
`000020
`
`
`
`1; Ex. 1004, 4:17-19. These cyclic oligosaccharides consist of ((cid:302)-1,4)-linked (cid:302)-D-
`
`glucopyranose units and contain a somewhat lipophilic central cavity and a
`
`hydrophilic outer surface. Ex. 1004, 4:19-21. As shown in the Figure 1 below, the
`
`natural (cid:302)-, (cid:533)- and (cid:534)-cyclodextrins ((cid:302)-CD, (cid:533)-CD and (cid:534)-CD) consist of six, seven,
`
`and eight glucopyranose units, respectively. Id., 4:30-5:2; Ex. 1014, 115. Figure 2
`
`shows schematically how the glucopyranose units form the central cavity. The
`
`diameter of the central cavity in (cid:302)-CD, (cid:533)-CD and (cid:534)-CD varies, being 0.47-0.53 nm,
`
`0.6-0.65 nm, or 0.75-0.83 nm respectively. Ex. 1056, 1018 (Table 1).
`
`Figure 1
`
`
`
`21
`
`000021
`
`
`
`Figure 2
`
`
`
`The natural cyclodextrins, in particular (cid:533)-CD, are of limited aqueous solubility,
`
`and complexes resulting from interaction of lipophiles with these cyclodextrins can
`
`also be of limited solubility, resulting in the precipitation of solid cyclodextrin
`
`complexes from water and other aqueous systems. Ex. 1044, 116, 1st col. This is
`
`thought to be due to relatively strong intermolecular hydrogen bonding in the
`
`crystal state. Ex. 1014, 80(2):144-50. Substitution of any of the hydrogen bond
`
`forming hydroxyl groups in cyclodextrins, even by lipophilic methoxy groups,
`
`results in dramatic improvements in the aqueous solubility of the cyclodextrin
`
`derivative. Id.
`
`36.
`
` Water-soluble cyclodextrin derivatives that are widely used in
`
`pharmaceutical formulations include the hydroxypropyl derivatives of (cid:533)-CD and
`
`(cid:534)-CD (HP-(cid:533)CD, HP-(cid:534)-CD) the randomly methylated (cid:533)-cyclodextrin (RM(cid:533)CD),
`
`22
`
`000022
`
`
`
`and sulfoalkylether cyclodextrins (SAE-CD) such as sulfobutylether-(cid:533)-
`
`cyclodextrin (SBE-(cid:533)-CD) and sulfobutylether-(cid:534)-cyclodextrin (SBE- (cid:534) CD). Ex.
`
`1004, 5:3-8. SAE-CDs have long been commercially available with different
`
`substitution levels of the SAE group, e.g., 1, 4, 7, and 8 sulfobutylether groups in
`
`SBE-(cid:533)CD. Ex. 1034, 4.
`
`37. Cyclodextrins solubilize drugs by forming inclusion and non-
`
`inclusion complexes. “In aqueous solution, cyclodextrins form inclusion
`
`complexes with many drugs through a process in which the water molecules
`
`located in the central cavity are replaced by either the whole drug molecule, or
`
`more frequently, by some lipophilic portion of the drug structure. Since no
`
`covalent bonds are formed or broken during the drug-cyclodextrin complex
`
`formation, the complexes are in dynamic equilibrium with free drug and
`
`cyclodextrin molecules.” Ex. 1004, 5:21-24, 26-28.
`
`38. Bhowmick discloses that olopatadine aqueous solutions having a
`
`concentration of 0.